SCHEMBL5467320

SCHEMBL5467320

CCOC(=O)N1CCC(O)(c2cccs2)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.55
HSD17B10 Q99714 1/20 0.55
L3MBTL1 Q9Y468 2/20 0.54
PKM P14618 2/20 0.53
BRD4 O60885 2/20 0.51
ALDH1A1 P00352 2/20 0.49
KDM4E B2RXH2 1/20 0.49
CHRM2 P08172 1/20 0.49
CHRM5 P08912 1/20 0.49
CHRM3 P20309 1/20 0.49
CYP2C9 P11712 2/20 0.48
CYP2C19 P33261 2/20 0.48
CYP3A4 P08684 1/20 0.48
TSHR P16473 1/20 0.48
OPRM1 P35372 1/20 0.48
OPRD1 P41143 1/20 0.48
OPRK1 P41145 1/20 0.48
OPRL1 P41146 1/20 0.48
CYP2D6 P10635 1/20 0.47
NOS3 P29474 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14033468 0.85 NOS2 (0.58) SMN1; SMN2HSD17B10ALDH1A1CYP2C9CYP2C19
SCHEMBL9311269 0.85 SMN1; SMN2 (0.48) SMN1; SMN2HSD17B10L3MBTL1PKMBRD4
SCHEMBL986690 0.83 GPR119 (0.47) SMN1; SMN2ALDH1A1TSHROPRM1OPRD1
SCHEMBL9311693 0.80 KMT2A (0.47) SMN1; SMN2HSD17B10L3MBTL1PKMBRD4
SCHEMBL9311700 0.80 KMT2A (0.47) SMN1; SMN2HSD17B10L3MBTL1PKMBRD4
SCHEMBL5467020 0.80 KMT2A (0.47) SMN1; SMN2HSD17B10L3MBTL1PKMBRD4
SCHEMBL9744559 0.80 KMT2A (0.47) SMN1; SMN2HSD17B10L3MBTL1PKMBRD4
SCHEMBL5467023 0.80 KMT2A (0.47) SMN1; SMN2HSD17B10L3MBTL1PKMBRD4
SCHEMBL4768465 0.80 OPRM1 (0.58) SMN1; SMN2ALDH1A1CHRM2CHRM5CHRM3
SCHEMBL5466581 0.80 L3MBTL1 (0.56) SMN1; SMN2HSD17B10L3MBTL1KDM4ECYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070185168-A1 Piperidine derivatives KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-08-09 US disclosed
EP-1736474-A1 PIPERIDINE DERIVATIVE KYOWA HAKKO KOGYO CO., LTD. (JP) 2006-12-27 EP disclosed
US-5292738-A Anti-virally active pyridazinamines JANSSEN PHARMACEUTICA N.V. (BE) 1994-03-08 US disclosed
US-5157035-A Viricides JANSSEN PHARMACEUTICA N. V. (BE) 1992-10-20 US disclosed
US-5001125-A Anti-virally active pyridazinamines JANSSEN PHARMACEUTICA N.V. (BE) 1991-03-19 US disclosed
EP-0156433-B1 ANTI-VIRALLY ACTIVE PYRIDAZINAMINES JANSSEN PHARMACEUTICA N.V. (BE) 1991-02-27 EP disclosed
US-4870087-A Indole containing, 2-thienyl-1,2,3,6-tetrahydropyridyls and their pharmaceutical use MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1989-09-26 US disclosed
EP-0156433-A2 Anti-virally active pyridazinamines JANSSEN PHARMACEUTICA N.V. (BE) 1985-10-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185168-A1 Piperidine derivatives GRIN2C, GRIN1, GRIN3A SMN1; SMN2 3033/4885HSD17B10 2210/4885L3MBTL1 2896/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.